Similarity Score |
Similarity Level |
Drug ID |
Developmental Stage |
0.8864 |
High Similarity |
NPD3027 |
Phase 3 |
0.8529 |
High Similarity |
NPD1613 |
Approved |
0.8529 |
High Similarity |
NPD1612 |
Clinical (unspecified phase) |
0.8271 |
Intermediate Similarity |
NPD2983 |
Phase 2 |
0.8271 |
Intermediate Similarity |
NPD2982 |
Phase 2 |
0.8248 |
Intermediate Similarity |
NPD6859 |
Clinical (unspecified phase) |
0.8235 |
Intermediate Similarity |
NPD1529 |
Clinical (unspecified phase) |
0.8231 |
Intermediate Similarity |
NPD1653 |
Approved |
0.8195 |
Intermediate Similarity |
NPD2981 |
Phase 2 |
0.8162 |
Intermediate Similarity |
NPD3018 |
Phase 2 |
0.8162 |
Intermediate Similarity |
NPD1530 |
Clinical (unspecified phase) |
0.8146 |
Intermediate Similarity |
NPD3817 |
Phase 2 |
0.8133 |
Intermediate Similarity |
NPD37 |
Approved |
0.8092 |
Intermediate Similarity |
NPD4966 |
Approved |
0.8092 |
Intermediate Similarity |
NPD4965 |
Approved |
0.8092 |
Intermediate Similarity |
NPD4967 |
Phase 2 |
0.8042 |
Intermediate Similarity |
NPD7266 |
Discontinued |
0.7974 |
Intermediate Similarity |
NPD4868 |
Clinical (unspecified phase) |
0.7895 |
Intermediate Similarity |
NPD1934 |
Approved |
0.7885 |
Intermediate Similarity |
NPD7199 |
Phase 2 |
0.7871 |
Intermediate Similarity |
NPD6234 |
Discontinued |
0.7852 |
Intermediate Similarity |
NPD1940 |
Clinical (unspecified phase) |
0.7852 |
Intermediate Similarity |
NPD422 |
Phase 1 |
0.7846 |
Intermediate Similarity |
NPD5283 |
Phase 1 |
0.7842 |
Intermediate Similarity |
NPD4908 |
Phase 1 |
0.782 |
Intermediate Similarity |
NPD1548 |
Phase 1 |
0.7812 |
Intermediate Similarity |
NPD7054 |
Approved |
0.7812 |
Intermediate Similarity |
NPD5844 |
Phase 1 |
0.7808 |
Intermediate Similarity |
NPD1652 |
Phase 2 |
0.7792 |
Intermediate Similarity |
NPD6374 |
Clinical (unspecified phase) |
0.7769 |
Intermediate Similarity |
NPD7843 |
Approved |
0.7764 |
Intermediate Similarity |
NPD7074 |
Phase 3 |
0.7764 |
Intermediate Similarity |
NPD7472 |
Approved |
0.775 |
Intermediate Similarity |
NPD7228 |
Approved |
0.7748 |
Intermediate Similarity |
NPD3687 |
Approved |
0.7748 |
Intermediate Similarity |
NPD3686 |
Approved |
0.7746 |
Intermediate Similarity |
NPD4060 |
Phase 1 |
0.7736 |
Intermediate Similarity |
NPD6167 |
Clinical (unspecified phase) |
0.7736 |
Intermediate Similarity |
NPD6168 |
Clinical (unspecified phase) |
0.7736 |
Intermediate Similarity |
NPD6166 |
Phase 2 |
0.773 |
Intermediate Similarity |
NPD4907 |
Clinical (unspecified phase) |
0.7727 |
Intermediate Similarity |
NPD2801 |
Approved |
0.7727 |
Intermediate Similarity |
NPD2393 |
Clinical (unspecified phase) |
0.7727 |
Intermediate Similarity |
NPD7157 |
Approved |
0.7721 |
Intermediate Similarity |
NPD1610 |
Phase 2 |
0.7721 |
Intermediate Similarity |
NPD3705 |
Approved |
0.7697 |
Intermediate Similarity |
NPD6055 |
Clinical (unspecified phase) |
0.7692 |
Intermediate Similarity |
NPD5123 |
Clinical (unspecified phase) |
0.7692 |
Intermediate Similarity |
NPD5124 |
Phase 1 |
0.7682 |
Intermediate Similarity |
NPD6980 |
Clinical (unspecified phase) |
0.7677 |
Intermediate Similarity |
NPD5402 |
Approved |
0.7676 |
Intermediate Similarity |
NPD6233 |
Phase 2 |
0.7673 |
Intermediate Similarity |
NPD7184 |
Clinical (unspecified phase) |
0.766 |
Intermediate Similarity |
NPD7095 |
Approved |
0.7647 |
Intermediate Similarity |
NPD3496 |
Discontinued |
0.7647 |
Intermediate Similarity |
NPD4678 |
Approved |
0.7647 |
Intermediate Similarity |
NPD4675 |
Approved |
0.764 |
Intermediate Similarity |
NPD3818 |
Discontinued |
0.7639 |
Intermediate Similarity |
NPD6653 |
Approved |
0.7635 |
Intermediate Similarity |
NPD4628 |
Phase 3 |
0.7635 |
Intermediate Similarity |
NPD4109 |
Clinical (unspecified phase) |
0.7635 |
Intermediate Similarity |
NPD4110 |
Phase 3 |
0.7634 |
Intermediate Similarity |
NPD5535 |
Approved |
0.7628 |
Intermediate Similarity |
NPD3882 |
Suspended |
0.7622 |
Intermediate Similarity |
NPD4338 |
Clinical (unspecified phase) |
0.7622 |
Intermediate Similarity |
NPD7808 |
Phase 3 |
0.7612 |
Intermediate Similarity |
NPD5536 |
Phase 2 |
0.7609 |
Intermediate Similarity |
NPD4379 |
Clinical (unspecified phase) |
0.76 |
Intermediate Similarity |
NPD6799 |
Approved |
0.76 |
Intermediate Similarity |
NPD6143 |
Clinical (unspecified phase) |
0.7597 |
Intermediate Similarity |
NPD2684 |
Approved |
0.7591 |
Intermediate Similarity |
NPD1091 |
Approved |
0.7584 |
Intermediate Similarity |
NPD6190 |
Approved |
0.7584 |
Intermediate Similarity |
NPD5307 |
Clinical (unspecified phase) |
0.758 |
Intermediate Similarity |
NPD7075 |
Discontinued |
0.758 |
Intermediate Similarity |
NPD7975 |
Clinical (unspecified phase) |
0.7569 |
Intermediate Similarity |
NPD6355 |
Discontinued |
0.7569 |
Intermediate Similarity |
NPD4340 |
Discontinued |
0.7566 |
Intermediate Similarity |
NPD5403 |
Approved |
0.7561 |
Intermediate Similarity |
NPD7251 |
Discontinued |
0.7557 |
Intermediate Similarity |
NPD228 |
Approved |
0.7551 |
Intermediate Similarity |
NPD5762 |
Approved |
0.7551 |
Intermediate Similarity |
NPD3540 |
Phase 1 |
0.7551 |
Intermediate Similarity |
NPD5763 |
Approved |
0.7548 |
Intermediate Similarity |
NPD6801 |
Discontinued |
0.7518 |
Intermediate Similarity |
NPD2861 |
Phase 2 |
0.75 |
Intermediate Similarity |
NPD7314 |
Clinical (unspecified phase) |
0.75 |
Intermediate Similarity |
NPD6232 |
Discontinued |
0.75 |
Intermediate Similarity |
NPD1357 |
Approved |
0.75 |
Intermediate Similarity |
NPD7993 |
Clinical (unspecified phase) |
0.75 |
Intermediate Similarity |
NPD7819 |
Suspended |
0.75 |
Intermediate Similarity |
NPD7096 |
Clinical (unspecified phase) |
0.75 |
Intermediate Similarity |
NPD5585 |
Approved |
0.75 |
Intermediate Similarity |
NPD6797 |
Phase 2 |
0.7484 |
Intermediate Similarity |
NPD7615 |
Clinical (unspecified phase) |
0.7483 |
Intermediate Similarity |
NPD4357 |
Discontinued |
0.7483 |
Intermediate Similarity |
NPD1511 |
Approved |
0.7483 |
Intermediate Similarity |
NPD6410 |
Clinical (unspecified phase) |
0.7483 |
Intermediate Similarity |
NPD3539 |
Phase 1 |
0.7483 |
Intermediate Similarity |
NPD6798 |
Discontinued |
0.7469 |
Intermediate Similarity |
NPD7473 |
Discontinued |
0.7466 |
Intermediate Similarity |
NPD7097 |
Phase 1 |
0.7465 |
Intermediate Similarity |
NPD5752 |
Clinical (unspecified phase) |
0.7455 |
Intermediate Similarity |
NPD7240 |
Approved |
0.745 |
Intermediate Similarity |
NPD6674 |
Discontinued |
0.7448 |
Intermediate Similarity |
NPD230 |
Phase 1 |
0.7438 |
Intermediate Similarity |
NPD8127 |
Discontinued |
0.7434 |
Intermediate Similarity |
NPD5401 |
Approved |
0.7431 |
Intermediate Similarity |
NPD4062 |
Phase 3 |
0.7415 |
Intermediate Similarity |
NPD7033 |
Discontinued |
0.7413 |
Intermediate Similarity |
NPD4625 |
Phase 3 |
0.741 |
Intermediate Similarity |
NPD7549 |
Discontinued |
0.741 |
Intermediate Similarity |
NPD1608 |
Approved |
0.7389 |
Intermediate Similarity |
NPD1465 |
Phase 2 |
0.7386 |
Intermediate Similarity |
NPD1512 |
Approved |
0.7385 |
Intermediate Similarity |
NPD1358 |
Approved |
0.7379 |
Intermediate Similarity |
NPD4140 |
Approved |
0.7379 |
Intermediate Similarity |
NPD1558 |
Phase 1 |
0.7375 |
Intermediate Similarity |
NPD5494 |
Approved |
0.7365 |
Intermediate Similarity |
NPD6032 |
Approved |
0.7358 |
Intermediate Similarity |
NPD4381 |
Clinical (unspecified phase) |
0.7357 |
Intermediate Similarity |
NPD4749 |
Approved |
0.7351 |
Intermediate Similarity |
NPD2219 |
Phase 1 |
0.7347 |
Intermediate Similarity |
NPD4536 |
Approved |
0.7347 |
Intermediate Similarity |
NPD4537 |
Clinical (unspecified phase) |
0.7347 |
Intermediate Similarity |
NPD4538 |
Approved |
0.7342 |
Intermediate Similarity |
NPD5353 |
Approved |
0.7333 |
Intermediate Similarity |
NPD4237 |
Approved |
0.7333 |
Intermediate Similarity |
NPD3060 |
Approved |
0.7333 |
Intermediate Similarity |
NPD4236 |
Phase 3 |
0.7333 |
Intermediate Similarity |
NPD5698 |
Clinical (unspecified phase) |
0.7333 |
Intermediate Similarity |
NPD4162 |
Approved |
0.7329 |
Intermediate Similarity |
NPD447 |
Suspended |
0.7324 |
Intermediate Similarity |
NPD6917 |
Clinical (unspecified phase) |
0.732 |
Intermediate Similarity |
NPD4123 |
Phase 3 |
0.732 |
Intermediate Similarity |
NPD7004 |
Clinical (unspecified phase) |
0.7319 |
Intermediate Similarity |
NPD17 |
Approved |
0.7319 |
Intermediate Similarity |
NPD1778 |
Approved |
0.7315 |
Intermediate Similarity |
NPD1375 |
Discontinued |
0.731 |
Intermediate Similarity |
NPD1726 |
Clinical (unspecified phase) |
0.7308 |
Intermediate Similarity |
NPD6599 |
Discontinued |
0.7308 |
Intermediate Similarity |
NPD4380 |
Phase 2 |
0.7305 |
Intermediate Similarity |
NPD8651 |
Approved |
0.7303 |
Intermediate Similarity |
NPD7124 |
Phase 2 |
0.7299 |
Intermediate Similarity |
NPD1894 |
Discontinued |
0.7285 |
Intermediate Similarity |
NPD3750 |
Approved |
0.7285 |
Intermediate Similarity |
NPD6398 |
Clinical (unspecified phase) |
0.7278 |
Intermediate Similarity |
NPD8455 |
Phase 2 |
0.7267 |
Intermediate Similarity |
NPD5677 |
Discontinued |
0.7261 |
Intermediate Similarity |
NPD6385 |
Approved |
0.7261 |
Intermediate Similarity |
NPD7411 |
Suspended |
0.7261 |
Intermediate Similarity |
NPD6386 |
Approved |
0.7252 |
Intermediate Similarity |
NPD290 |
Approved |
0.7248 |
Intermediate Similarity |
NPD2796 |
Approved |
0.7248 |
Intermediate Similarity |
NPD1551 |
Phase 2 |
0.7248 |
Intermediate Similarity |
NPD2438 |
Suspended |
0.7246 |
Intermediate Similarity |
NPD6559 |
Discontinued |
0.7244 |
Intermediate Similarity |
NPD4005 |
Discontinued |
0.7239 |
Intermediate Similarity |
NPD5242 |
Approved |
0.7234 |
Intermediate Similarity |
NPD4359 |
Approved |
0.7222 |
Intermediate Similarity |
NPD1008 |
Clinical (unspecified phase) |
0.7222 |
Intermediate Similarity |
NPD6832 |
Phase 2 |
0.7214 |
Intermediate Similarity |
NPD1535 |
Discovery |
0.7208 |
Intermediate Similarity |
NPD3536 |
Discontinued |
0.7208 |
Intermediate Similarity |
NPD3146 |
Approved |
0.7208 |
Intermediate Similarity |
NPD3688 |
Clinical (unspecified phase) |
0.7208 |
Intermediate Similarity |
NPD4378 |
Clinical (unspecified phase) |
0.7206 |
Intermediate Similarity |
NPD6671 |
Approved |
0.7205 |
Intermediate Similarity |
NPD919 |
Approved |
0.72 |
Intermediate Similarity |
NPD1550 |
Clinical (unspecified phase) |
0.72 |
Intermediate Similarity |
NPD1552 |
Clinical (unspecified phase) |
0.7194 |
Intermediate Similarity |
NPD6516 |
Phase 2 |
0.7194 |
Intermediate Similarity |
NPD5846 |
Approved |
0.7194 |
Intermediate Similarity |
NPD4626 |
Approved |
0.719 |
Intermediate Similarity |
NPD6667 |
Approved |
0.719 |
Intermediate Similarity |
NPD5058 |
Phase 3 |
0.719 |
Intermediate Similarity |
NPD6666 |
Approved |
0.7188 |
Intermediate Similarity |
NPD7768 |
Phase 2 |
0.7183 |
Intermediate Similarity |
NPD3225 |
Approved |
0.7181 |
Intermediate Similarity |
NPD5588 |
Approved |
0.7181 |
Intermediate Similarity |
NPD5960 |
Phase 3 |
0.7181 |
Intermediate Similarity |
NPD3748 |
Approved |
0.7178 |
Intermediate Similarity |
NPD7229 |
Phase 3 |
0.7176 |
Intermediate Similarity |
NPD968 |
Approved |
0.7176 |
Intermediate Similarity |
NPD3134 |
Approved |
0.717 |
Intermediate Similarity |
NPD5773 |
Approved |
0.717 |
Intermediate Similarity |
NPD5772 |
Approved |
0.7169 |
Intermediate Similarity |
NPD7804 |
Clinical (unspecified phase) |
0.7163 |
Intermediate Similarity |
NPD1481 |
Phase 2 |
0.7163 |
Intermediate Similarity |
NPD2231 |
Phase 2 |
0.7163 |
Intermediate Similarity |
NPD2235 |
Phase 2 |
0.7162 |
Intermediate Similarity |
NPD2653 |
Approved |
0.7152 |
Intermediate Similarity |
NPD1549 |
Phase 2 |
0.7152 |
Intermediate Similarity |
NPD970 |
Clinical (unspecified phase) |
0.7143 |
Intermediate Similarity |
NPD7038 |
Approved |
0.7143 |
Intermediate Similarity |
NPD7039 |
Approved |
0.7143 |
Intermediate Similarity |
NPD7685 |
Pre-registration |
0.7143 |
Intermediate Similarity |
NPD3619 |
Clinical (unspecified phase) |
0.7143 |
Intermediate Similarity |
NPD3847 |
Discontinued |
0.7143
|
Intermediate Similarity |
NPD3620 |
Phase 2 |